Skip to content
God Of Sound – Lifestyle
Author:
Vivani Medical, Inc.
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
July 7, 2026
Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.
July 2, 2026
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker
June 26, 2026
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
June 25, 2026
Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention
June 22, 2026
Vivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026
May 28, 2026
Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update
May 13, 2026